Marketing gets under way for type 2 diabetes combo drug.
PRINCETON, N.J. -- Novo Nordisk Inc. and Shionogi Co.'s Sciele Pharma Inc. unit have begun marketing PrandiMet (repaglinide and metformin HCl) tablets.
The medication is said to be the first and only fixed-dose combination of the short-acting secretagogue repaglinide and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the United States.
Scientists at Novo Nordisk and Sciele Pharma note that PrandiMet is a meglitinide and biguanide combination product that should be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a meglitinide and metformin HCl or who have in adequate glycemic control on a meglitinide alone or a metformin HCl alone.
Both companies stress that the drug should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis.
Novo Nordisk and Sciele Pharma explain that PrandiMet targets three primary abnormalities of type 2 diabetes by stimulating the release of insulin from the pancreas, improving insulin sensitivity and decreasing gluconeogenesis.
The combination of metformin and repaglinide has been shown to reduce A1c levels effectively.
Although the two drugs have been used together for more than a decade, PrandiMet is the first treatment option that combines both medications into one pill.
In other news, a recent report from the pharmaceutical and health care research and advisory firm Decision Resources says that because of its broad portfolio of insulin drugs, Novo Nordisk will remain the leading company in the worldwide metabolism sector through 2014.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RX/Diabetes Care|
|Publication:||Chain Drug Review|
|Article Type:||Brief article|
|Date:||Mar 16, 2009|
|Previous Article:||Promotion at Novo Nordisk.|
|Next Article:||CE catalog highlights.|